Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.7488
+0.0688 (10.12%)
At close: Aug 22, 2025, 4:00 PM
0.7600
+0.0112 (1.50%)
After-hours: Aug 22, 2025, 7:59 PM EDT
Company Description
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Klotho Neurosciences, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| ISIN Number | US49876K1034 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board and Secretary |
| Jeffrey LeBlanc | Chief Financial Officer |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor and Director |
| Peter J. Moriarty | Chief Business Officer |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Advisor and Consultant |
| Dr. Bradford A. Navia M.D., Ph.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 12, 2025 | 8-K | Current Report |
| Jul 28, 2025 | 424B5 | Filing |
| Jul 28, 2025 | 424B3 | Prospectus |
| Jul 28, 2025 | 424B3 | Prospectus |
| Jul 25, 2025 | EFFECT | Notice of Effectiveness |
| Jul 23, 2025 | 8-K/A | [Amend] Current report |
| Jul 22, 2025 | 8-K | Current Report |
| Jul 18, 2025 | 8-K | Current Report |